Open AccessResults of antiviral treatment of patients with chronic hepatitis C: experience of Poznan centre
Author(s) -
Maciej Bura,
Arleta KowalaPiaskowska,
Agnieszka Adamek,
Aleksandra Bura,
Arkadiusz Czajka,
Katarzyna Hryckiewicz,
Iwona Bereszyńska,
Iwona MozerLisewska
Publication year - 2012
Publication title -
postępy higieny i medycyny doświadczalnej
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.275
H-Index - 34
eISSN - 1732-2693
pISSN - 0032-5449
DOI - 10.5604/17322693.1000332
Subject(s) - medicine , ribavirin , viremia , hepatocellular carcinoma , hepatitis c virus , gastroenterology , cirrhosis , population , pegylated interferon , hepatitis c , viral load , liver biopsy , immunology , virus , biopsy , environmental health
Hepatitis C virus (HCV) infection in Poland affects approximately 750 thousand persons. The prevention of cirrhosis and hepatocellular carcinoma, of which approximately 20% of patients with chronic hepatitis C virus are at risk, aims at eradication of the virus by applying antiviral treatment with pegylated interferon alpha with ribavirin.